Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER

References

• Kadin ME, Kamoun M, Lamberg J. Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N Engl J Med. 1981;304(11):648–653. doi:10.1056/NEJM198103123041106
   PubMed Web of Science ®Google Scholar
• Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood. 1990;75(11):2213–2219. doi:10.1182/blood.V75.11.2213.2213
   PubMed Web of Science ®Google Scholar
• Jaffe ESHN, Stein H, Vardiman J. World Health Organization Classification of Tumours/Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2001.
   Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Foss FM, Horwitz SM, Civallero M, et al. Incidence and outcomes of rare T cell lymphomas from the T cell project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol. 2020;95(2):151–155. doi:10.1002/ajh.25674
   PubMed Web of Science ®Google Scholar
• Yabe M, Medeiros LJ, Wang SA, et al. Distinguishing between hepatosplenic T-cell lymphoma and γδ T-cell large granular lymphocytic leukemia: a clinicopathologic, immunophenotypic, and molecular analysis. Am J Surg Pathol. 2017;41(1):82–93. doi:10.1097/PAS.0000000000000743
   PubMed Web of Science ®Google Scholar
• Yabe M, Medeiros LJ, Tang G, et al. Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases. Am J Surg Pathol. 2016;40(5):676–688. doi:10.1097/PAS.0000000000000614
   PubMed Web of Science ®Google Scholar
• Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009;20(6):1080–1085. doi:10.1093/annonc/mdn751
   PubMed Web of Science ®Google Scholar
• Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102(13):4261–4269. doi:10.1182/blood-2003-05-1675
   PubMed Web of Science ®Google Scholar
• Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J. 2015;5(6):e318. doi:10.1038/bcj.2015.43
   PubMed Web of Science ®Google Scholar
• Pro B, Allen PB, Behdad A. Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood. 2020;136(18):2018–2026. doi:10.1182/blood.2019004118
   PubMed Web of Science ®Google Scholar
• Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol. 2001;25(3):285–296. doi:10.1097/00000478-200103000-00002
   PubMed Web of Science ®Google Scholar
• Paes VR, de Lima PP, Siqueira SAC. Hemophagocytic lymphohistiocytosis associated with hepatosplenic T-cell lymphoma: case report. Autops Case Rep. 2014;4(4):19–24. doi:10.4322/acr.2014.035
   PubMedGoogle Scholar
• Voss MH, Lunning MA, Maragulia JC, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk. 2013;13(1):8–14. doi:10.1016/j.clml.2012.09.002
   PubMed Web of Science ®Google Scholar
• Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4(5):511–522. doi:10.1016/j.crohns.2010.05.006
   PubMed Web of Science ®Google Scholar
• Yabe M, Medeiros LJ, Daneshbod Y, et al. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. Ann Diagn Pathol. 2017;26:16–22. doi:10.1016/j.anndiagpath.2016.10.005
   PubMed Web of Science ®Google Scholar
• Montgomery M, van Santen MM, Biemond BJ, Diamond RH, Pals ST. Hepatosplenic T-cell lymphoma: a Population-Based Study assessing incidence and association with immune-mediated disease. Gastroenterol Hepatol. 2015;11(3):160–163.
   Google Scholar
• Subramaniam K, Yeung D, Grimpen F, et al. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014;44(3):287–290. doi:10.1111/imj.12363
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–1394. doi:10.1200/JCO.2015.63.8387
   PubMed Web of Science ®Google Scholar
• Huang X, Sun Q, Fu H, Zhou X, Guan X, Wang J. Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China. Pathol Res Pract. 2014;210(6):351–356. doi:10.1016/j.prp.2014.02.004
   PubMed Web of Science ®Google Scholar
• Koh YW, Hwang HS, Park CS, Yoon DH, Suh C, Huh J. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. Leuk Lymphoma. 2015;56(9):2630–2636. doi:10.3109/10428194.2015.1004169
   PubMed Web of Science ®Google Scholar
• Wang C, Wang Y, Cao J, et al. Elevated expression of HMGB1 is prognostic of poor survival in patients with relapsed/refractory T/NK-CL. Ann Hematol. 2021;100(9):2293–2302. doi:10.1007/s00277-021-04473-4
   PubMed Web of Science ®Google Scholar
• Xu P, Yu D, Wang L, Shen Y, Shen Z, Zhao W. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients. Ann Hematol. 2015;94(2):239–247. doi:10.1007/s00277-014-2188-8
   PubMed Web of Science ®Google Scholar
• Xue T, Yu BH, Yan WH, et al. Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma. Hematol Oncol. 2020;38(5):665–672. doi:10.1002/hon.2778
   PubMed Web of Science ®Google Scholar
• Liu Y, Shen J, Awal Issah M, Liu T, Zhou H, Fu H. CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis? J Int Med Res. 2020;48(5):300060520918087.
   PubMed Web of Science ®Google Scholar
• Sekiguchi Y, Shimada A, Imai H, et al. CD56+ angioimmunoblastic T-cell lymphoma with evans syndrome: a case report and review of the literature. J Clin Exp Hematop. 2013;53(1):37–47. doi:10.3960/jslrt.53.37
   PubMedGoogle Scholar
• Sun Y, Wan J, Song Q, et al. Prognostic significance of CD56 antigen expression in patients with de novo non-M3 acute myeloid leukemia. Biomed Res Int. 2021;2021:1929357. doi:10.1155/2021/1929357
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Z, Xia ZJ, Lu Y, Huang HQ, Zhang YJ. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis. Tumour Biol. 2015;36(10):7717–7723. doi:10.1007/s13277-015-3485-0
   PubMedGoogle Scholar
• Saito T, Matsuno Y, Tanosaki R, Watanabe T, Kobayashi Y, Tobinai K. Gamma delta T-cell neoplasms: a clinicopathological study of 11 cases. Ann Oncol. 2002;13(11):1792–1798. doi:10.1093/annonc/mdf293
   PubMed Web of Science ®Google Scholar
• Tanase A, Schmitz N, Stein H, et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT lymphoma working party. Leukemia. 2015;29(3):686–688. doi:10.1038/leu.2014.280
   PubMed Web of Science ®Google Scholar
• Lai R, Larratt LM, Etches W, et al. Hepatosplenic T-cell lymphoma of alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia. Am J Surg Pathol. 2000;24(3):459–463. doi:10.1097/00000478-200003000-00016
   PubMed Web of Science ®Google Scholar